Oxford Drug Design awarded £1m to progress uUTI treatment 24 Feb Written by Alexandra Collingbourne Alexandra Collingbourne Previous Previous Healx doses first subject in Phase II neurofibromatosis type 1 therapy trial Next Next FLIT to ramp up electric bike production as investors pump in £1.2m
Oxford Drug Design awarded £1m to progress uUTI treatment 24 Feb Written by Alexandra Collingbourne Alexandra Collingbourne